Free Trial

Can Teladoc Stock Be Resuscitated?

Teledoc stock price forecast

Key Points

  • Teladoc is the world’s largest virtual healthcare platform due to its earlier acquisitions of Better Health and Livongo.
  • BetterHealth was acquired by Teladoc in 2015 for just under $5 million and has grown its annual revenues north of $1 billion in 2022.
  • Livongo was acquired for $18.5 billion in 2020, and Teladoc took a ($13 billion) impairment charge in 2022.
  • Teladoc will enter the weight-loss and prediabetic management segment with its physician-based care service in Q3 2023.
  • Teladoc losses continue to decrease as the stock tries to break out of an eight-month trading range.
  • Teladoc shares have a 15.96% short interest.
  • 5 stocks we like better than Teladoc Health.

Virtual healthcare services company Teladoc Health Inc. NYSE: TDOC has had a treacherous journey rising to a high of $308 in Feb 2021 and falling to a post-pandemic low of $21.60 in January 2023. The company saw its stock price catapulted higher during the pandemic as short-staffed hospitals prioritized COVID-19 emergencies. Elective care and routine doctor visits were shut down during the pandemic, and many healthcare stocks performed well.

Teladoc provided a way to meet with a medical practitioner conveniently and virtually, seeking treatment and advice from home. Shares could be setting up for a breakout through its weekly rectangle range, especially after announcing its entry into the physician-based weight loss management segment to commence in Q3 2023.

Becoming a Giant

Teladoc became the most extensive virtual health provider by acquiring the diabetes management telemedicine platform Livongo for $18.5 billion in 2020. The company was and is still losing money. However, the sentiment was strong, and shares remained triple-digit until normalization kicked in as consumers returned to doctors offices and resumed elective procedures. This accelerated the downward trajectory for the company.

Livongo Bust

Unfortunately, the Livongo acquisition led to a ($13 billion) goodwill impairment charge in the following two years. This means they overpaid for a company doing just over $300 million in 2020. However, Teladoc’s $4.5 million acquisition of behavioral health platform Better Health in 2015 hit the jackpot growing into the world's largest online therapy service, growing revenues by 43% annually to $1 billion by 2022. 

BetterHelp Boom

BetterHelp provides on-demand counseling and behavioral and mental health services conveniently through its virtual platform accessible via mobile devices and desktop computers. Its services are provided through banners targeting specific audiences like Faithful Counseling targeting Christians, Pride Counseling targeting the LGBTQ, and Terappeuta targeting Spanish-speaking customers. As it grew in popularity, the company found more ways to monetize its growing database. Unfortunately, Better Help was rocked by a scandal that threatened to undermine trust in the company. 

Betrayal of Trust Settlement

BetterHelp committed a "betrayal of trust," according to the Federal Trade Commission (FTC), by sharing sensitive patient health data with third parties, including significant ad platforms including Meta Platforms Inc. NASDAQ: META, Snap Inc. NASDAQ: SNAP and Pinterest NASDAQ: PINS. What made it worse was that the company misrepresented that it wouldn't share customer information with other parties, which it did to secure more advertising sales. The FTC claims BetterHelp shared the health information of seven million consumers with advertisers. The FTC is negotiating a $7.8 million settlement with BetterHelp.

Top Line Growing Again

On April 26, 2022, Teladoc released its fiscal first-quarter 2023 results for the quarter ending March 2023. The company reported an adjusted earnings-per-share (EPS) loss of (-$0.42) excluding non-recurring items, versus consensus analyst estimates for a loss of ($0.49), beating estimates by $0.07. Revenues rose 11.3% year-over-year (YOY) to $629.24 million, beating analyst estimates for $618.24 million. Many expenses occurred in the first quarter, including ($46 million) in stock-based compensation, restructuring costs of ($8.1 million) and amortization of acquired intangibles of ($50.3 million).

Teladoc CEO Jason Gorevic commented, "With a strong financial position, we can fund and invest in innovations and a world-class team of medical professionals as we support leading employers, health plans, hospital systems, and governments around the world. We have solid momentum heading into the rest of the year as the market embraces Teladoc Health's unified whole-person care experience."

Downside Guidance

Teladoc lowered its fiscal Q2 2023 revenue guidance between $635 million to $660 million versus $642.72 million. The company expects fiscal full-year 2023 revenue guidance to come between $2.575 billion and $2.675 billion versus $2.61 consensus analyst estimates. EPS losses are expected between ($0.55) to ($0.45) versus ($0.37). Full-year 2023 EPS losses are expected between ($1.70) to ($1.25) versus ($1.31) consensus analyst estimates.   

Entering the Weight Management Segment

In the similar steps taken by WW International Inc. NASDAQ: WW entering the prescription weight-loss drug prescription business with its acquisition of Sequence Inc., Teladoc will also be implementing its own weight-management and prediabetic care service. The service will enable customers to receive physician prescriptions for weight loss drugs if necessary. The weight loss drug segment is on fire, led by Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY. They anticipate the expansion to commence in Q3 2023. Teladoc analyst ratings and price targets can be found on MarketBeat.

 

Weekly Rectangle Range

The weekly candlestick chart on TDOC illustrates the rectangle trading range its been barcoding at since September 2022. The upper trendline is $34.21, with the lower trendline at $21.60, the swing low on January 2023. Shares staged a rally triggering the weekly market structure low (MSL) breakout through 26.98 as it retested the upper trendline of $34.21 again at the end of January 2023.

The weekly market structure high (MSH) sell triggered the breakdown below $28.93 before the weekly stochastic crossed back up, attempting to trigger the weekly MSL again at $26.98. Pullback support levels are at $26.31, $25.00, $23.10 and $21.60 weekly swing low.

Should you invest $1,000 in Teladoc Health right now?

Before you consider Teladoc Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.

While Teladoc Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Jea Yu
About The Author

Jea Yu

Contributing Author

Trading Strategies

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Teladoc Health (TDOC)
2.7079 of 5 stars
$10.40+15.6%N/A-1.80Hold$12.08
Meta Platforms (META)
4.553 of 5 stars
$563.09-0.4%0.36%26.52Moderate Buy$634.10
Snap (SNAP)
3.6301 of 5 stars
$10.62+0.2%N/A-18.30Hold$14.31
Pinterest (PINS)
4.8151 of 5 stars
$29.31+0.3%N/A97.70Moderate Buy$42.00
WW International (WW)
2.587 of 5 stars
$1.01+6.3%N/A-0.17Hold$4.50
Novo Nordisk A/S (NVO)
4.2406 of 5 stars
$102.77-2.4%0.70%33.26Moderate Buy$144.50
Eli Lilly and Company (LLY)
4.9913 of 5 stars
$748.91-0.6%0.69%80.96Moderate Buy$1,007.94
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

These Top Stocks in 2024 Will Continue to be Big Winners in 2025
’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines